good earnings but i don’t like
$Vir Biotechnology(VIR.US$ small scale experiments are good.
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start voting against as a gesture.
The flu project is nothing, but price never recover. Too expensive comparing to regular flu shot
Unless you pivot to an IT company selling services to make riches look better, and get IT company valuation.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
